Entry Detail



General Information

Database ID:exR0088195
RNA Name:hsa-miR-34c-5p
RNA Type:miRNA
Chromosome:chr11
Starnd:+
Coordinate:
Start Site(bp):111513451End Site(bp):111513473
External Links:hsa-miR-34c-5p



Disease Information

Disease Name:Breast Cancer
Disease Category:Cancers
MeSH ID:D001943
Type:Neoplasms/Breast Neoplasms
Alias:Breast Neoplasms//Breast Neoplasm//Neoplasm, Breast//Breast Tumors//Breast Tumor//Tumor, Breast//Tumors, Breast//Neoplasms, Breast//Breast Cancer//Cancer, Breast//Mammary Cancer//Cancer, Mammary//Cancers, Mammary//Mammary Cancers//Malignant Neoplasm of Breast//Breast Malignant Neoplasm//Breast Malignant Neoplasms//Malignant Tumor of Breast//Breast Malignant Tumor//Breast Malignant Tumors//Cancer of Breast//Cancer of the Breast//Mammary Carcinoma, Human//Carcinoma, Human Mammary//Carcinomas, Human Mammary//Human Mammary Carcinomas//Mammary Carcinomas, Human//Human Mammary Carcinoma//Mammary Neoplasms, Human//Human Mammary Neoplasm//Human Mammary Neoplasms//Neoplasm, Human Mammary//Neoplasms, Human Mammary//Mammary Neoplasm, Human//Breast Carcinoma//Breast Carcinomas//Carcinoma, Breast//Carcinomas, Breast



Expression Detail

GEO ID:GSE101841
Description:Serum microRNA profile of Her2 positive metastatic breast cancer patients
Experimental Design:Trastuzumab therapy
Case Disease Type:Breast Cancer
Case Disease SubType:HER2 positive metastatic breast cancer
Case Sample:Breast Cancer Trastuzumab resistant
Control Sample:Trastuzumab sensitive
Number of Case:42
Number of Control:61
Number of Samples:103





Regulatory Relationship

mRNA targets:
Gene SymbolChromosomeStart Site(bp)End Site(bp)Strand
ZDHHC17
chr12
76763588
76853696
+
PHF19
chr9
120855651
120894896
-
CD151
chr11
832887
839831
+
ATXN7L3
chr17
44191805
44200113
-
TNRC6B
chr22
40044817
40335808
+
GATAD2B
chr1
153789030
153923360
-
SEC61A1
chr3
128051641
128071683
+
NFAT5
chr16
69565094
69704666
+
NPTX1
chr17
80466834
80477843
-
TMEM109
chr11
60914158
60923443
+
SUPT6H
chr17
28662198
28702679
+
ARPP19
chr15
52547045
52569883
-
PXDC1
chr6
3722614
3752026
-
TRIO
chr5
14143342
14532128
+
AGTRAP
chr1
11736084
11754802
+
NCOA1
chr2
24491914
24770702
+
JRK
chr8
142657460
142681968
-
TOB2
chr22
41433494
41446801
-
NFKBIA
chr14
35401511
35404749
-
ANGEL1
chr14
76786168
76826246
-
MTMR9
chr8
11284816
11328146
+
AMER1
chrX
64185117
64205708
-
NECTIN1
chr11
119623408
119729200
-
MRPL19
chr2
75646783
75690851
+
IGSF3
chr1
116574399
116667755
-
FOSL1
chr11
65892049
65900573
-
TKFC
chr11
61333210
61353295
+
CRTC3
chr15
90529923
90645345
+
FGFRL1
chr4
1009936
1026898
+
ZIC5
chr13
99962964
99971909
-
miRNA targets:NA
circRNA targets:
circRNA SymbolChromosomeStart Site(bp)End Site(bp)Strand
hsa_circ_0001723
chr7
91924202
91948826
+
hsa_circ_0001495
chr5
68470703
68471364
+
hsa_circ_0000943
chr19
47421744
47440665
+
hsa_circ_0000038
chr1
28800065
28802803
+
hsa_circ_0001865
chr9
86292641
86293514
-
hsa_circ_0001146
chr20
34241449
34246936
-
hsa_circ_0001164
chr20
45891031
45923523
-
lncRNA targets:
lncRNA SymbolChromosomeStart Site(bp)End Site(bp)Strand
AC018521.1
chr17
47945424
47981736
+
AC116913.1
chr15
66488658
66492109
-
HCG18
chr6
30286690
30327382
-
KCNQ1OT1
chr11
2608328
2699994
-
LINC00665
chr19
36313067
36331770
-
NEAT1
chr11
65422774
65445540
+
SNHG7
chr9
136721366
136728184
-
TERC
chr3
169764520
169765060
-
XIST
chrX
73820649
73852723
-
Display:



Experiment Detail

GEO ID:GSE101841
Sample Source:Blood
Source Fraction:Serum
Platform:GPL23138
Method:Microarray
Num of detected RNA Type:1
Num of detected RNAs of this Type:1808
Sample treatment protocol:NA
RNA Extract protocol:Total RNA was extracted from 103 samples with the Plasma RNA Purification Mini Kit (51000, NorgenBiotek Corporation, Canada), following manufacturer's instructions.
RNA library preparation protocol:Total RNA extracted from 600ul serum was employed with 100 nmol/L of pCp-DY647 and 15 Units of T4 RNA ligase in a total reaction volume of 20 ul at 16°C overnight.



Reference

PMID:29691399
Title:A serum microRNA signature predicts trastuzumab benefit in HER2-positive metastatic breast cancer patients.
Author:Li H, Liu J, Chen J, Wang H, Yang L, Chen F, Fan S, Wang J, Shao B, Yin D, Zeng M, Li M, Li J, Su F, Liu Q, Yao H, Su S, Song E
Journal:Nat Commun. 2018 Apr 24;9(1):1614.
Description:MicroRNAs (miRNAs) have been used to predict therapeutic effects for various cancers, but whether miRNAs can serve as biomarkers for HER2+ metastatic breast cancer (MBC) patients remains unclear.